Collegium Pharmaceutical Debt

COLL Stock  USD 33.35  0.11  0.33%   
Collegium Pharmaceutical has over 674.28 Million in debt which may indicate that it relies heavily on debt financing. At this time, Collegium Pharmaceutical's Long Term Debt Total is quite stable compared to the past year. Debt To Equity is expected to rise to 3.26 this year, although the value of Debt To Assets will most likely fall to 0.50. . Collegium Pharmaceutical's financial risk is the risk to Collegium Pharmaceutical stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Collegium Pharmaceutical's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Collegium Pharmaceutical's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Collegium Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Collegium Pharmaceutical's stakeholders.
For most companies, including Collegium Pharmaceutical, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Collegium Pharmaceutical, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Collegium Pharmaceutical's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
4.5909
Book Value
7.269
Operating Margin
0.3517
Profit Margin
0.1478
Return On Assets
0.0968
At this time, Collegium Pharmaceutical's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 1.4 B this year, although the value of Non Current Liabilities Other will most likely fall to about 6.2 M.
  
Check out the analysis of Collegium Pharmaceutical Fundamentals Over Time.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

Collegium Pharmaceutical Bond Ratings

Collegium Pharmaceutical financial ratings play a critical role in determining how much Collegium Pharmaceutical have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Collegium Pharmaceutical's borrowing costs.
Piotroski F Score
5
HealthyView
Beneish M Score
(2.81)
Unlikely ManipulatorView

Collegium Pharmaceutical Debt to Cash Allocation

Many companies such as Collegium Pharmaceutical, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Collegium Pharmaceutical currently holds 674.28 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity.

Collegium Pharmaceutical Total Assets Over Time

Collegium Pharmaceutical Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Collegium Pharmaceutical uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Collegium Pharmaceutical Debt Ratio

    
  50.0   
It seems Collegium Pharmaceutical uses both, debt and equity to finance its assets. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Collegium Pharmaceutical's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Collegium Pharmaceutical, which in turn will lower the firm's financial flexibility.

Collegium Pharmaceutical Corporate Bonds Issued

Collegium Short Long Term Debt Total

Short Long Term Debt Total

814.2 Million

At this time, Collegium Pharmaceutical's Short and Long Term Debt Total is quite stable compared to the past year.

Understaning Collegium Pharmaceutical Use of Financial Leverage

Leverage ratios show Collegium Pharmaceutical's total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of Collegium Pharmaceutical's financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
Last ReportedProjected for Next Year
Short and Long Term Debt Total775.4 M814.2 M
Net Debt500.6 M525.7 M
Long Term Debt556.4 M584.2 M
Short Term Debt212 M222.6 M
Short and Long Term Debt210.8 M221.4 M
Long Term Debt Total619.2 M650.2 M
Net Debt To EBITDA 1.27  1.21 
Debt To Equity 3.11  3.26 
Interest Debt Per Share 20.21  21.22 
Debt To Assets 0.68  0.50 
Long Term Debt To Capitalization 0.64  0.67 
Total Debt To Capitalization 0.89  0.85 
Debt Equity Ratio 3.11  3.26 
Debt Ratio 0.68  0.50 
Cash Flow To Debt Ratio 0.37  0.39 
Please read more on our technical analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
Check out the analysis of Collegium Pharmaceutical Fundamentals Over Time.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.49)
Earnings Share
2.34
Revenue Per Share
18.538
Quarterly Revenue Growth
0.165
Return On Assets
0.0968
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.